Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Roger buying again

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Apr 18, 2022 5:00pm

290 Views

Post# 34611368

RE:RE:RE:RE:RE:RE:Roger buying again

Glad you noticed it Fred ... ;-)

It indeed confirms that they have a deal with PHAC and that our anti-virus platform shows enough impressive efficacy ratios, that they could move faster on this one. So the PHAC Dr. Kobasa's comment on a canadian-made vaccine and flexible platform against many types of viruses (H1N1 Influenza, Zika, Herpes Simplex and Corona viruses - Biological Safety Level (“BSL”) 2 and 3). The flexibility of our platform interests the canadian government.

BioNtech was first launched to address cancer but never developed it. They moved in 2018 to anti-virus (influenza/Zike, etc ...) via a deal with Pfizer and then jumped on the COVID-19 opportunity. Now, they're trying to come back to cancer (but they're not addressing the destruction of solid tumors like we are).

So TLT management decided that COVID-19 was less risky and would take less time to get valuation, over the risky GBM indication that requires long follow-ups. But they will proceed with NSCLC, the #1 cancer in both the US and Canada. 20x more lung cancer cases than GBM ones.

So we would prove efficient on 2 different types of platforms:

- oncology (NMIBC, NSCLC (and GBM in preclinical))
- anti-virus (COVID-19 is now a reality (6th wave) and not going away anytime soon and anti-viruses platforms are rare, governments have noticed)

That would be managing the risk, when you read the following stats:

The American Cancer Society’s estimates for lung cancer in the United States for 2022 are:

About 236,740 new cases of lung cancer (117,910 in men and 118,830 in women)
About 130,180 deaths from lung cancer (68,820 in men and 61,360 in women)

Lung cancer is by far the leading cause of cancer death , making up almost 25% of all cancer deaths. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined.

Glioblastoma Facts & Figures

Glioblastoma (or GBM) is one of the most complex, deadly, and treatment-resistant cancers.
More than 13,000 Americans are expected to receive a GBM diagnosis in 2020.
GBM accounts for 48% of all primary malignant brain tumors.
It is estimated that more than 10,000 individuals in the United States will succumb to glioblastoma every year.
The five-year survival rate for glioblastoma patients is only 6.8%, and the average length of survival for glioblastoma patients is estimated to be only 12 to 18 months.
Survival rates and mortality statistics for GBM have been virtually unchanged for decades.
Despite first being identified in the scientific literature in the 1920’s, there have only been four drugs and one device ever approved by the FDA for the treatment of glioblastoma.
None of these treatments have succeeded in significantly extending patient lives beyond a few extra months.
Some patients have a glioblastoma upon diagnosis (de novo or primary GBM), while other patients’ tumors start as another, lower-grade type of brain tumor and over time progress into a glioblastoma (secondary GBM). A vast majority of GBM diagnoses are de novo.
Mean age at diagnosis is 64.
In addition to being life-threatening, GBM – and its harsh treatments – inflict devastation upon the brain, which controls cognition, mood, behavior, and every function of every organ and body part.
Many patients will lose their ability to work, drive, and a host of other functions that contribute to one’s sense of self and independence.
Glioblastoma is also one of the more expensive cancers to treat, often leaving patients and families with major financial hardship on top of the burdens of the disease.